ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.95 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

August 25, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential ↗

August 18, 2025

ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy.

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential ↗

August 16, 2025

ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick.

Via Chartmill

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts ↗

June 05, 2025

Via Benzinga

Acadia (ACAD) Q2 Revenue Rises 9% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates ↗

August 06, 2025

Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month.

Via Chartmill

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

August 06, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

August 04, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation ↗

July 25, 2025

ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech.

Via Chartmill

What Analysts Are Saying About ACADIA Pharmaceuticals Stock ↗

July 24, 2025

Via Benzinga

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

July 23, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗

July 22, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors.

Via Chartmill

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation ↗

July 04, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth...

Via Chartmill

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

June 25, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential ↗

June 24, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities.

Via Chartmill

13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know ↗

June 23, 2025

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock ↗

June 12, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth...

Via Chartmill

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

June 09, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory ↗

June 06, 2025

Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent.

Via Benzinga

Topics Intellectual Property

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

June 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation ↗

May 22, 2025

ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.